• Mer. Lug 17th, 2024

Multiple Myeloma

  • Home
  • Multiple Myeloma , Plitidepsin (Aplidin® PharmaMar) will be re-evaluated by the EMA

Multiple Myeloma , Plitidepsin (Aplidin® PharmaMar) will be re-evaluated by the EMA

PharmaMar (MSE:PHM) has received a notification from the European Commission (EC) informing the Company of its decision to revoke the refusal to grant Marketing Authorization for plitidepsin (Aplidin®) in Multiple…